SCHEMBL6727353

SCHEMBL6727353

NC(=O)[C@]1(O)OCCN1c1ccc(N2CCOCC2)c(F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 7/20 0.48
LMNA P02545 2/20 0.48
MAOA P21397 2/20 0.48
PTGS1 P23219 1/20 0.48
CALML3 P27482 1/20 0.48
SDHA P31040 1/20 0.48
NPC1 O15118 4/20 0.48
HPGD P15428 3/20 0.47
RAB9A P51151 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
TP53 P04637 1/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47
MAPK1 P28482 1/20 0.47
ALDH1A1 P00352 2/20 0.47
HTT P42858 1/20 0.42
KMT2A Q03164 1/20 0.41
F10 P00742 1/20 0.41
SLC6A5 Q9Y345 1/20 0.41
SLC6A9 P48067 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27546292 0.74 NPC1 (0.49) MAOBLMNAMAOAPTGS1CALML3
SCHEMBL1397520 0.72 HPGD (0.68) LMNANPC1HPGDRAB9ASMN1; SMN2
Bicarbonate SCHEMBL3548870 0.71 HTT (0.61) LMNANPC1HPGDRAB9ASMN1; SMN2
Bicarbonate SCHEMBL28763043 0.70 HTT (0.60) LMNANPC1HPGDRAB9ASMN1; SMN2
SCHEMBL6955366 0.70 ALDH1A1 (0.71) LMNANPC1HPGDRAB9ASMN1; SMN2
SCHEMBL5624637 0.70 NPC1 (0.46) MAOBLMNAMAOAPTGS1CALML3
SCHEMBL3042307 0.70 MAOA (0.73) MAOBLMNAMAOAPTGS1CALML3
SCHEMBL18803820 0.69 HPGD (0.53) LMNANPC1HPGDRAB9ASMN1; SMN2
SCHEMBL27674823 0.69 HTT (0.59) LMNANPC1HPGDRAB9ASMN1; SMN2
SCHEMBL6727354 0.69 MAOB (0.48) MAOBLMNAMAOAPTGS1CALML3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147760-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY 2004-07-29 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147760-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 MAOB 976/4885LMNA 3385/4885MAOA 957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.